Please assess the completion status of the following clinical trial:

Trial Title: Anecortave Acetate Risk-Reduction Trial (AART)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Dry AMD in study eye, Wet AMD in non-study eye;~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Under 50;~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 15 mg Anecortave Acetate (Type: EXPERIMENTAL): Anecortave Acetate Sterile Suspension, 30 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
- 30 mg Anecortave Acetate (Type: EXPERIMENTAL): Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
- Anecortave Acetate Vehicle (Type: SHAM_COMPARATOR): Anecortave Acetate Vehicle, one sham injection in the study eye every 6 months for 48 months

Based on this trial design, predict the completion outcome and termination type (if applicable).